Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.

This review discusses various treatments for androgenetic alopecia, including minoxidil, finasteride, dutasteride, ketoconazole, and experimental options, but reports limited clinical trial evidence for efficacy.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This review discusses the role of skeletal muscle in synthesizing bioactive androgens, highlighting that intramuscular androgens may influence muscle via intracrine action, but their precise function remains unclear.

This review discusses hormone-modulating therapies for androgen-mediated cutaneous disorders in women but reports no new clinical results and highlights the need for more rigorous studies.

In this study, several compounds, including estrogen and Dutasteride, showed neuroprotective effects on dopaminergic neurons in an MPTP mouse model of Parkinson's disease.

Mesotherapy shows promise for cellulite and facial rejuvenation but has mixed results for body sculpting and hair loss, with more research needed for safety and effectiveness.

This review discusses various biologics for hair aging but reports no agent capable of reversing the natural aging process of hair.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.

This study found that coating liquid crystalline nanoparticles with chitosan significantly enhanced the skin permeation of 5α-reductase inhibitors, suggesting a promising strategy for improving topical delivery in androgenetic alopecia treatment.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This study reported that in rat retinas under high pressure, allopregnanolone synthesis increased and helped reduce pressure-induced damage through GABAA receptors, suggesting potential therapeutic use in glaucoma.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.

This study found that using hair steroid profiling, dutasteride treatment led to reduced dihydrotestosterone levels and DHT/testosterone ratio in patients with male-pattern baldness.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This report describes two cases of gynecomastia linked to the use of Finasteride (Propecia®) for treating androgenetic alopecia, highlighting a rare but important side effect.

This review highlights the potential for clinicians to recognize skin manifestations as a straightforward method to detect insulin resistance and improve management of diabetes and obesity.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

Stopping sunscreen use on the forehead led to hair regrowth in a woman with frontal fibrosing alopecia.

This review examines hormonal therapies, including finasteride, dutasteride, spironolactone, and oral contraceptives, for treating hidradenitis suppurativa, summarizing various clinical study outcomes but reporting no new clinical results.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.